PER-030-09已完成未知
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 17 至 75（—）
- 性别
- All
入选标准
- •Subjects male or female 17 to 75 years old
- •They suffered a mild to moderate unilateral painful sprained, distended or bruised wrist no more than 60 hours before randomization
- •Presence of pain of at least 50 points and not greater than 90 points, on a Visual Analog Scale (VAS) of 100 points validated in randomization
- •Ability and desire to comply with all procedures defined in the protocol including the filling of an electronic journal every day
排除标准
- •Open wound or infection at the site of wrist pain, or evidence of severe injury including fracture or nerve injury
- •Presence of any acute or chronic pain in addition to that of the wrist specified in the study, eg. pain due to concurrent injury that occurred at the time of the sprain, strain or bruise or a chronic condition such as osteoarthritis or gout, etc.
- •Sprained, distended or bruised wrist or sprained, bilateral distended or bruised
- •Prior injury, or onset of tendinitis or bursitis on the same wrist within 3 months of the current injury
- •Presence of tendonitis or bursitis
- •History of injury or paresis in a nerve of the hand, wrist or forearm (eg carpal tunnel syndrome), in the limb that qualifies for the study
- •Active skin disease that includes the potential site of patch application
- •Use of aspirin (except in a stable low-dose cardiovascular prophylaxis regimen, if started before the injury) or short-lived NSAIDs within 12 hours prior to randomization, or use of long-lived NSAIDs within 24 hours before randomization
- •Use of systemic opioids within 24 hours prior to randomization, or use of topical opioids within 12 hours prior to randomization
- •Use of oral or parenteral corticosteroid medications within 30 days prior to randomization
- •Topical treatment (including physical therapy) applied in the pain region within 12 hours of randomization, other than ice packs or simple compression.
- •History of ulcerative peptic disease within one year of randomization, any history of gastrointestinal bleeding or coagulation abnormality (with the exception of bleeding due to internal or external hemorrhoids)
- •Clinically significant pulmonary, gastrointestinal, hepatic, renal, endocrine or cardiovascular disease, poorly controlled
- •History of intolerance or hypersensitivity including asthma, after taking aspirin or another nonsteroidal anti-inflammatory drug (NSAID) including diclofenac
- •History of acetaminophen intolerance (study rescue medication)
- •History of foot sensitivity! to adhesives (eg adhesive tape)
- •Treatment with a drug or experimental device within 30 days prior to randomization
- •Positive urine pregnancy test in women of childbearing age
- •Positive urine test for drug abuse.
研究者
相似试验
进行中（未招募）
1 期
Assessment of efficacy and safety in patients with non-cancer-related pain and opioid-induced constipation.Opioid-induced constipation (OIC)EUCTR2011-001987-24-SKAstraZeneca AB630
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ESBiogen Idec Research Limited290
进行中（未招募）
1 期
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2013-001870-38-SEGrifols Therapeutics Inc.339
进行中（未招募）
1 期
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858EUCTR2019-004789-17-FRGalderma S.A.240
招募中
3 期
Chronic Migraine in Patients 12 to 17 Years of AgeCTRI/2021/07/034818Eli Lilly and Company India Pvt Ltd